{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:03:39Z","timestamp":1779296619336,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.ajo.2009.08.005","type":"journal-article","created":{"date-parts":[[2009,10,29]],"date-time":"2009-10-29T04:13:00Z","timestamp":1256789580000},"page":"147-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Pegaptanib Sodium for Macular Edema Secondary to Branch Retinal Vein Occlusion"],"prefix":"10.1016","volume":"149","author":[{"given":"John J.","family":"Wroblewski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"John A.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine R.","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2009.08.005_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1442-9071.1993.tb00959.x","article-title":"An anatomical study of retinal arteriovenous crossings and their role in the pathogenesis of retinal branch vein occlusions","volume":"21","author":"Jefferies","year":"1993","journal-title":"Aust N Z J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib2","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/archopht.1982.01030040110020","article-title":"Histopathologic study of branch retinal vein occlusion","volume":"100","author":"Frangieh","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/bjo.67.3.137","article-title":"Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion","volume":"67","author":"Trope","year":"1983","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/archinte.1978.03630260030012","article-title":"Systemic factors contributory to retinal vein occlusion","volume":"138","author":"McGrath","year":"1978","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ajo.2009.08.005_bib5","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1160\/TH04-11-0768","article-title":"Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis?","volume":"93","author":"Janssen","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ajo.2009.08.005_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/02713680701851902","article-title":"Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities","volume":"33","author":"Rehak","year":"2008","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ajo.2009.08.005_bib7","first-page":"265","article-title":"Branch retinal vein occlusion: clinical findings, natural history, and management","volume":"7","author":"Margolis","year":"2006","journal-title":"Compr Ophthalmol Update"},{"key":"10.1016\/j.ajo.2009.08.005_bib8","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ophtha.2007.01.010","article-title":"Interventions for branch retinal vein occlusion: an evidence-based systematic review","volume":"114","author":"McIntosh","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.08.005_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/archopht.1986.01050130044017","article-title":"Argon laser scatter photocoagulation for prevention of neovascularization and hemorrhage in branch vein occlusion","volume":"104","year":"1986","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib10","first-page":"OP178","article-title":"The natural course of temporal retinal branch vein occlusion","volume":"78","author":"Gutman","year":"1974","journal-title":"Trans Am Acad Ophthalmol Otolaryngol"},{"key":"10.1016\/j.ajo.2009.08.005_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0161-6420(83)34542-5","article-title":"Ocular neovascularization with retinal occlusion: III. Incidence of neovascularization with retinal vascular occlusion","volume":"90","author":"Hayreh","year":"1983","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.08.005_bib12","first-page":"488","article-title":"Macular edema in branch retinal vein occlusion: prognosis and management","volume":"83","author":"Gutman","year":"1977","journal-title":"Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol"},{"key":"10.1016\/j.ajo.2009.08.005_bib13","first-page":"219","article-title":"The influence of ticlopidine on the natural course of retinal vein occlusion","volume":"15","author":"Houtsmuller","year":"1984","journal-title":"Agents Actions Suppl"},{"key":"10.1016\/j.ajo.2009.08.005_bib14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0002-9394(14)75791-5","article-title":"A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin","volume":"118","author":"Glacet-Bernard","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0750-7658(86)80148-4","article-title":"Role of acute normovolemic hemodilution in treating retinal venous occlusions","volume":"5","author":"Poupard","year":"1986","journal-title":"Ann Fr Anesth Reanim"},{"key":"10.1016\/j.ajo.2009.08.005_bib16","first-page":"514","article-title":"Randomized study of the effect of isovolemic hemodilution in retinal branch vein occlusion","volume":"85","author":"Hansen","year":"1988","journal-title":"Fortschr Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0002-9394(84)90316-7","article-title":"Argon laser photocoagulation for macular edema in branch vein occlusion","volume":"98","year":"1984","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/00006982-200510000-00006","article-title":"Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion","volume":"25","author":"Cekic","year":"2005","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2009.08.005_bib19","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ajo.2005.12.011","article-title":"Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion","volume":"141","author":"Chen","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/sj.eye.6702518","article-title":"Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion","volume":"22","author":"Patel","year":"2008","journal-title":"Eye"},{"key":"10.1016\/j.ajo.2009.08.005_bib21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/IAE.0b013e318154b9d1","article-title":"Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation","volume":"28","author":"Cakir","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2009.08.005_bib22","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archopht.1988.01060140633037","article-title":"Surgical decompression of branch retinal vein occlusions","volume":"106","author":"Osterloh","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.ajo.2004.06.061","article-title":"Vitrectomy with or without arteriovenous adventitial sheathotomy for macular edema associated with branch retinal vein occlusion","volume":"138","author":"Yamamoto","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000098504","article-title":"Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen) in diabetic retinopathy","volume":"39","author":"Starita","year":"2007","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib25","first-page":"1774","article-title":"Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor","volume":"50","author":"Senger","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajo.2009.08.005_bib26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ajo.2009.08.005_bib27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00417-004-1087-4","article-title":"Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion","volume":"244","author":"Noma","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.eye.6702498","article-title":"Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion","volume":"22","author":"Noma","year":"2008","journal-title":"Eye"},{"key":"10.1016\/j.ajo.2009.08.005_bib29","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.120.12.1644","article-title":"Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion","volume":"120","author":"Boyd","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0008-4182(05)80078-X","article-title":"Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration","volume":"40","author":"Ng","year":"2005","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ajo.2009.08.005_bib32","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2009.08.005_bib33","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","article-title":"A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema","volume":"112","author":"Cunningham","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.08.005_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ophtha.2005.10.012","article-title":"Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals","volume":"113","author":"Adamis","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.08.005_bib35","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archophthalmol.2009.14","article-title":"Pegaptanib sodium for macular edema secondary to central retinal vein occlusion","volume":"127","author":"Wroblewski","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib36","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1182\/blood.V93.11.3811","article-title":"Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1","volume":"93","author":"Mechtcheriakova","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ajo.2009.08.005_bib37","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00417-002-0576-6","article-title":"Functional role of Egr-1 mediating VEGF-induced tissue factor expression in the retinal capillary endothelium","volume":"240","author":"Sassa","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib38","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/bjo.2007.127282","article-title":"Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial","volume":"92","author":"Prager","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/bjo.2007.123513","article-title":"Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion","volume":"92","author":"Kreutzer","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00417-008-0916-2","article-title":"One-year results after intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion","volume":"247","author":"Jaissle","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthamol"},{"key":"10.1016\/j.ajo.2009.08.005_bib41","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mt.2008.10","article-title":"Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator","volume":"16","author":"Campochiaro","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajo.2009.08.005_bib42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IAE.0b013e318030e77e","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion","volume":"27","author":"Rabena","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2009.08.005_bib43","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/IAE.0b013e3181619bee","article-title":"Comparison of two doses of intravitreal bevacizumab (Avastin) for the treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up","volume":"28","author":"Wu","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2009.08.005_bib44","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/IAE.0b013e3181aa8dfe","article-title":"Safety and efficacy of intravitreal bevacizumab (Avastin) for the management of branch and hemiretinal vein occlusion","volume":"29","author":"Gregori","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2009.08.005_bib45","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2009.08.005_bib46","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2009.08.005_bib47","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2009.08.005_bib48","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1167\/iovs.02-0807","article-title":"VEGF164 is proinflammatory in the diabetic retina","volume":"44","author":"Ishida","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2009.08.005_bib49","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1084\/jem.20022027","article-title":"VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization","volume":"198","author":"Ishida","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.ajo.2009.08.005_bib50","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ajo.2009.08.005_bib51","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0002-9440(10)65138-3","article-title":"Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris","volume":"155","author":"Blaauwgeers","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajo.2009.08.005_bib52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","article-title":"Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury","volume":"171","author":"Nishijima","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajo.2009.08.005_bib53","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study","volume":"98","author":"Klein","year":"2000","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ajo.2009.08.005_bib54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0002-9394(00)00709-1","article-title":"Systemic diseases associated with various types of retinal vein occlusion","volume":"131","author":"Hayreh","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib55","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ophtha.2008.09.046","article-title":"Cerebrovascular accidents in ranibizumab","volume":"116","author":"Ueta","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.08.005_bib56","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/bjo.2007.132597","article-title":"Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the V.I.S.I.O.N. trial","volume":"92","author":"Singerman","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.08.005_bib57","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ajo.2004.11.011","article-title":"Multiple laser treatments for macular edema attributable to branch retinal vein occlusion","volume":"139","author":"Esrick","year":"2005","journal-title":"Am J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939409005534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939409005534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T12:59:47Z","timestamp":1757595587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939409005534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0002939409005534"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2009.08.005","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegaptanib Sodium for Macular Edema Secondary to Branch Retinal Vein Occlusion","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2009.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}